Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti‐tumour necrosis factor treatment
AUTOR(ES)
Klooster, Peter M ten
FONTE
BMJ Group
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2111636Documentos Relacionados
- Anti‐tumour necrosis factor α therapy in patients with impaired renal function
- Optic neuritis occurring with anti‐tumour necrosis factor α therapy
- Switching between anti‐tumour necrosis factors: trying to get a handle on a complex issue
- Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours
- Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis.